Pfizer has launched a cost-savings programme on the TrumpRx platform aimed at lowering prescription drug prices for millions of Americans, expanding access to a wide range of its medicines across multiple therapeutic areas.
Under the programme, which took effect on 5 February 2026, more than 30 Pfizer brands will be available at significant discounts off list prices. The medicines span areas including women’s health, migraine, arthritis, rare diseases and other chronic conditions.
The initiative forms part of Pfizer’s broader Most Favoured Nation agreement with the US government, designed to reduce out-of-pocket drug costs for American patients while supporting continued pharmaceutical innovation.
Through TrumpRx, both uninsured patients and insured patients who choose to self-pay outside their insurance coverage can access discounts of up to 85 per cent, with average savings of around 50 per cent on most of Pfizer’s primary care medicines and selected specialty treatments. The programme is expected to benefit patients affected by conditions such as migraine, rheumatoid arthritis, menopause, atopic dermatitis and overactive bladder, collectively impacting more than 100 million people in the US.
Pfizer is working with GoodRx to broaden access to discounted medicines, allowing patients to use coupons at most US pharmacies or opt for select home-delivery services. In parallel, the company plans to continue expanding its PfizerForAll direct-to-consumer platform, launched in 2024, to give patients greater control over how they access healthcare and prescription treatments.
The company emphasised that the TrumpRx initiative reflects its ongoing efforts to improve affordability and accessibility of innovative medicines for American patients while aligning drug prices more closely with global benchmarks.
Also Read